Ritonavir is the best alternative to ketoconazole as an index inhibitor of cytochrome P450-3A in drug-drug interaction studies

British Journal of Clinical Pharmacology

Volumn 80, Issue 3, 2015, Pages 342-350

  Greenblatt, David J ^a   Harmatz, Jerold S ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

clarithromycin; cytochrome P450 3A; drug drug interactions; itraconazole; ketoconazole; ritonavir

Indexed keywords

CLARITHROMYCIN; COBICISTAT; CYTOCHROME P450 3A INHIBITOR; ITRACONAZOLE; KETOCONAZOLE; MIDAZOLAM; RITONAVIR; CYP3A PROTEIN, HUMAN; CYTOCHROME P450 3A;

AREA UNDER THE CURVE; ARTICLE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG INTERACTION; DRUG METABOLISM; DRUG SAFETY; HUMAN; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; DRUG DESIGN; FOOD AND DRUG ADMINISTRATION; METABOLISM; UNITED STATES;

AREA UNDER CURVE; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 CYP3A INHIBITORS; DRUG DESIGN; DRUG INTERACTIONS; HUMANS; KETOCONAZOLE; MIDAZOLAM; RITONAVIR; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84940453037     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12668     Document Type: Article

References (114)

1. FDA Drug Safety Communication: FDA limits usage of Nizoral (ketoconazole) oral tablets due to potentially fatal liver injury and risk of drug interactions and adrenal gland problems. UCM 362444: 26 July 2013.
2. European Medicines Agency recommends suspension of marketing authorisations for oral ketoconazole. Benefit of oral ketoconazole does not outweigh risk of liver injury in fungal infections. EMA/458028/2013. 26 July 2013.
3. FDA advises against using oral ketoconazole in drug interaction studies due to serious potential side effects. UCM 371017: 16 October 2013.
4. Greenblatt HK, Greenblatt DJ,. Liver injury associated with ketoconazole: Review of the published evidence. J Clin Pharmacol 2014; 54: 1321-9.
5. Raschi E, Poluzzi E, Koci A, Caraceni P, Ponti FD,. Assessing liver injury associated with antimycotics: Concise literature review and clues from data mining of the FAERS database. World Journal of Hepatology 2014; 6: 601-12.
6. Greenblatt DJ,. The ketoconazole legacy. Clinical Pharmacology in Drug Development 2014; 3: 1-3.
7. Greenblatt DJ, von Moltke LL,. Clinical studies of drug-drug interactions: design and interpretation. In: Enzyme and Transporter-Based Drug-Drug Interactions: Progress and Future Challenges, eds Pang KS, Rodrigues AD, Peter RM. New York: Springer, 2010; 625-49.
8. Ke AB, Zamek-Gliszczynski MJ, Higgins JW, Hall SD,. Itraconazole and clarithromycin as ketoconazole alternatives for clinical CYP3A inhibition studies. Clin Pharmacol Ther 2014; 95: 473-6.
9. Olkkola KT, Backman JT, Neuvinen PJ,. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994; 55: 481-5.
10. Tsunoda SM, Velez RL, von Moltke LL, Greenblatt DJ,. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole. Clin Pharmacol Ther 1999; 66: 461-71.
11. McCrea J, Prueksaritanont T, Gertz BJ, Carides A, Gillen L, Antonello S, Brucker MJ, Miller-Stein C, Osborne B, Waldman S,. Concurrent administration of the erythromycin breath test (EBT) and oral midazolam as in vivo probes for CYP3A activity. J Clin Pharmacol 1999; 39: 1212-20.
12. Lee JI, Chaves-Gnecco D, Amico JA, Kroboth PD, Wilson JW, Frye RF,. Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping. Clin Pharmacol Ther 2002; 72: 718-28.
13. Lam YW, Alfaro CL, Ereshefsky L, Miller M,. Pharmacokinetic and pharmacodynamic interactions of oral midazolam with ketoconazole, fluoxetine, fluvoxamine, and nefazodone. J Clin Pharmacol 2003; 43: 1274-82.
14. Eap CB, Buclin T, Cucchia G, Zullino D, Hustert E, Bleiber G, Golay KP, Aubert A-C, Baumann P, Telenti A, Kerb R,. Oral administration of a low dose of midazolam (75 μg) as an in vivo probe for CYP3A activity. Eur J Clin Pharmacol 2004; 60: 237-46.
15. Chung E, Nafziger AN, Kazierad DJ, Bertino JS,. Comparison of midazolam and simvastatin as cytochrome P450 3A probes. Clin Pharmacol Ther 2006; 79: 350-61.
16. Halama B, Hohmann N, Burhenne J, Weiss J, Mikus G, Haefeli WE,. A nanogram dose of the CYP3A probe substrate midazolam to evaluate drug interactions. Clin Pharmacol Ther 2013; 93: 564-71.
17. Stoch SA, Friedman E, Maes A, Yee K, Xu Y, Larson P, FitzGerald M, Chodakewitz J, Wagner JA,. Effect of different durations of ketoconazole dosing on the single-dose pharmacokinetics of midazolam: Shortening the paradigm. J Clin Pharmacol 2009; 49: 398-406.
18. Krishna G, Moton A, Ma L, Savant I, Martinho M, Seiberling M, McLeod J,. Effects of oral posaconazole on the pharmacokinetic properties of oral and intravenous midazolam: A Phase I, randomized, open-label, crossover study in healthy volunteers. Clin Ther 2009; 31: 286-98.
19. Kasichayanula S, Boulton DW, Luo W-L, Rodrigues AD, Yang Z, Goodenough A, Lee M, Jemal M, LaCreta F,. Validation of 4β-hydroxycholesterol and evaluation of other endogenous biomarkers for the assessment of CYP3A activity in healthy subjects. Br J Clin Pharmacol 2014; 78: 1122-34.
20. Olkkola K, Ahonen J, Neuvonen P,. The effect of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Anesthesthesia and Analgesia 1996; 82: 511-6.
21. Ahonen J, Olkkola K, Neuvonen P,. Effect of itraconazole and terbinafine on the pharmacokinetics and pharmacodynamics of midazolam in healthy volunteers. Br J Clin Pharmacol 1995; 40: 270-2.
22. Backman JT, Kivistö KT, Olkkola KT, Neuvonen PJ,. The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. Eur J Clin Pharmacol 1998; 54: 53-8.
23. Templeton I, Peng CC, Thummel KE, Davis C, Kunze KL, Isoherranen N,. Accurate prediction of dose-dependent CYP3A4 inhibition by itraconazole and its metabolites from in vitro inhibition data. Clin Pharmacol Ther. 2010; 88: 499-505.
24. Yeates RA, Laufen H, Zimmermann T,. Interaction between midazolam and clarithromycin: comparison with azithromycin. Int J Clin Pharmacol Ther 1996; 34: 400-5.
25. Gorski JC, Jones DR, Haehner-Daniels BD, Hamman MA, O'Mara EM, Hall SD,. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithormycin. Clin Pharmacol Ther 1998; 64: 133-43.
26. Gurley B, Hubbard MA, Williams DK, Thaden J, Tong Y, Gentry B, Breen P, Carrier DJ, Cheboyina S,. Assessing the clinical significance of botanical supplementation on human cytochrome P450 3A activity: Comparison of a milk thistle and black cohosh product to rifampin and clarithromycin. J Clin Pharmacol 2006; 46: 201-13.
27. Quinney SK, Haehner BD, Rhoades MB, Lin Z, Gorski JC, Hall SD,. Interaction between midazolam and clarithromycin in the elderly. Br J Clin Pharmacol 2008; 65: 98-109.
28. Markert C, Hellwig R, Burhenne J, Hoffmann MM, Weiss J, Mikus G, Haefeli W,. Interaction of ambrisentan with clarithromycin and its modulation by polymorphic SLCO1B1. Eur J Clin Pharmacol 2013; 69: 1785-93.
29. Yeh RF, Gaver VE, Patterson KB, Rezk NL, Baxter-Meheux F, Blake MJ, Eron JJ, Klein CE, Rublein JC, Kashuba ADM,. ritonavir induces /ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers. J Acquir Immune Defic Syndr 2006; 42: 52-60.
30. Wyen C, Fuhr U, Frank D, Aarnoutse RE, Klaassen T, Lazar A, Seeringer A, Doroshyenko O, Kirchheiner JC, Abdulrazik F, Schmeisser N, Lehmann C, Hein W, Schömig E, Burger DM, Fätkenheuer G, Jetter A,. Effect of an antiretroviral regimen containing ritonavir boosted ritonavir induces on intestinal and hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected patients. Clin Pharmacol Ther 2008; 84: 75-82.
31. Greenblatt DJ, Peters DE, Oleson LE, Harmatz JS, MacNab MW, Berkowitz N, Zinny MA, Court MH,. Inhibition of oral midazolam clearance by boosting doses of ritonavir, and by 4,4-dimethyl-benziso-(2H)-selenazine (ALT-2074), an experimental catalytic mimic of glutathione oxidase. Br J Clin Pharmacol. 2009; 68: 920-7.
32. Knox TA, Oleson L, von Moltke LL, Kaufman RC, Wanke CA, Greenblatt DJ,. Ritonavir greatly impairs CYP3A activity in HIV infection with chronic viral hepatitis. JAIDS 2008; 49: 358-68.
33. Schmitt C, Hofmann C, Riek M, Patel A, Zwanziger E,. Effect of saquinavir-ritonavir on cytochrome P450 3A4 activity in healthy volunteers using midazolam as a probe. Pharmacotherapy 2009; 29: 1175-81.
34. Kirby BJ, Collier AC, Kharasch ED, Whittington D, Thummel KE, Unadkat JD,. Complex drug interactions of HIV protease inhibitors 1: Inactivation, induction, and inhibition of cytochrome P450 3A by ritonavir or nelfinavir. Drug Metab Dispos 2011; 39: 1070-8.
35. Katzenmaier S, Markert C, Riedel KD, Burhenne J, Haefeli WE, Mikus G,. Determining the time course of CYP3A inhibition by potent reversible and irreversible CYP3A inhibitors using a limited sampling strategy. Clin Pharmacol Ther 2011; 90: 666-73.
36. Ieiri I, Tsunemitsu S, Maeda K, Ando Y, Izumi N, Kimura M, Yamane N, Okuzono T, Morishita M, Kotani N, Kanda E, Deguchi M, Matsuguma K, Matsuki S, Hirota T, Irie S, Kusuhara H, Sutiyama Y,. Mechanisms of pharmacokinetic enhancement between ritonavir and saquinavir; Micro/small dosing tests using midazolam (CYP3A4), fexofenadine (P-glycoprotein), and pravastatin (OATP1B1) as probe drugs. J Clin Pharmacol 2013; 53: 654-61.
37. Ancrenaz V, Deglon J, Samer C, Staub C, Dayer P, Daali Y, Desmeules J,. Pharmacokinetic interaction between prasugrel and ritonavir in healthy volunteers. Basic Clin Pharmacol Toxicol 2013; 112: 132-7.
38. Eichbaum C, Cortese M, Blank A, Burhenne J, Mikus G,. Concentration effect relationship of CYP3A inhibition by ritonavir in humans. Eur J Clin Pharmacol 2013; 69: 1795-800.
39. Morcos PN, Chang L, Kulkarni R, Giraudon M, Shulman N, Brennan BJ, Smith PF, Tran JQ,. A randomised study of the effect of danoprevir/ritonavir or ritonavir on substrates of cytochrome P450(CYP)3A and 2C9 in chronic hepatitis C patients using a drug cocktail. Eur J Clin Pharmacol 2013; 69: 1939-49.
40. Mathias AA, German P, Murray BP, Wei L, Jain A, West S, Warren D, Hui J, Kearney BP,. Pharmacokinetics and pharmacodynamics of GS-9350: A novel pharmacokinetic enhancer without anti-HIV activity. Clin Pharmacol Ther 2010; 87: 322-9.
41. Venkatakrishnan K, von Moltke LL, Greenblatt DJ,. Effects of the antifungal agents on oxidative drug metabolism in humans: clinical relevance. Clin Pharmacokinet 2000; 38: 111-80.
42. Niwa T, Imagawa Y, Yamazaki H,. Drug interactions between nine antifungal agents and drugs metabolized by human Cytochromes P450. Curr Drug Metab 2014; 15: 651-79.
43. Galetin A, Ito K, Hallifax D, Houston JB,. CYP3A4 substrate selection and substitution in the prediction of potential drug-drug interactions. J Pharmacol Exp Ther 2005; 314: 180-90.
44. Fahmi OA, Hurst S, Plowchalk D, Cook J, Guo F, Youdim K, Dickins M, Phipps A, Darekar A, Hyland R, Obach RS,. Comparison of different algorithms for predicting clinical drug-drug interactions, based on the use of CYP3A4 in vitro data: Predictions of compounds as precipitants of interaction. Drug Metab Dispos 2009; 37: 1658-66.
45. Zhao P, Ragueneau-Majlessi I, Zhang L, Strong JM, Reynolds KS, Levy RH, Thummel KE, Huang S-M,. Quantitative evaluation of pharmacokinetic inhibition of CYP3A substrates by ketoconazole: A simulation study. J Clin Pharmacol 2009; 49: 351-9.
46. Greenblatt DJ, Zhao Y, Venkatakrishnan K, Duan SX, Harmatz JS, Parent SJ, Court MH, von Moltke LL,. Mechanism of cytochrome P450-3A inhibition by ketoconazole. J Pharm Pharmacol. 2011; 63: 214-21.
47. Greenblatt DJ, Venkatakrishnan K, Harmatz JS, Parent SJ, von Moltke LL,. Sources of variability in ketoconazole inhibition of human cytochrome P450-3A in vitro. Xenobiotica 2010; 40: 713-20.
48. Daneshmend TK, Warnock DW,. Clinical pharmacokinetics of ketoconazole. Clin Pharmacokinet 1988; 14: 13-34
49. Greenblatt DJ, von Moltke LL, Harmatz JS, Mertzanis P, Graf JA, Durol ALB, Counihan M, Roth-Schechter B, Shader RI,. Kinetic and dynamic interaction study of zolpidem with ketoconazole, itraconazole, and fluconazole. Clin Pharmacol Ther 1998; 64: 661-71.
50. Greenblatt DJ,. Drug interaction studies with CYP3A substrates: How much inhibitor pre-exposure is needed? Clinical Pharmacology in Drug Development 2012; 1: 83-4.
51. Fuchs I, Hafner-Blumenstiel V, Markert C, Burhenne J, Weiss J, Haefeli WE, Mikus G,. Effect of the CYP3A inhibitor ketoconazole on the PXR-mediated induction of CYP3A activity. Eur J Clin Pharmacol 2013; 69: 507-13.
52. Back DJ, Tjia JF,. Comparative effects of the antimycotic drugs ketoconazole, fluconazole, itraconazole and terbinafine on the metabolism of cyclosporin by human liver microsomes. Br J Clin Pharmacol 1991; 32: 624-6.
53. von Moltke LL, Greenblatt DJ, Duan SX, Harmatz JS, Shader RI,. Inhibition of triazolam hydroxylation by ketoconazole, itraconazole, hydroxyitraconazole and fluconazole in vitro. Pharmacy and Pharmacology Communications 1998; 4: 443-5.
54. Tran TH, von Moltke LL, Venkatakrishnan K, Granda BW, Gibbs MA, Obach RS, Harmatz JS, Greenblatt DJ,. Microsomal protein concentration modifies the apparent inhibitory potency of CYP3A inhibitors. Drug Metab Dispos 2002; 30: 1441-5.
55. von Moltke LL, Greenblatt DJ, Schmider J, Duan SX, Wright CE, Harmatz JS, Shader RI,. Midazolam hydroxylation by human liver microsomes in vitro: Inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents. J Clin Pharmacol 1996; 36: 783-91.
56. Isoherranen N, Kunze KL, Allen KE, Nelson WL, Thummel KE,. Role of itraconazole metabolites in CYP3A4 inhibition. Drug Metab Dispos 2004; 32: 1121-31.
57. Templeton IE, Thummel KE, Kharasch ED, Kunze KL, Hoffer C, Nelson WL, Isoherranen N,. Contribution of itraconazole metabolites to inhibition of CYP3A4 in vivo. Clin Pharmacol Ther 2008; 83: 77-85.
58. Barone JA, Koh JG, Bierman RH, Colaizzi JL, Swanson KA, Gaffar MC, Moskovitz BL, Mechlinski W, van de Velde V,. Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers. Antimicrob Agents Chemother 1993; 37: 778-84.
59. Prentice AG, Glasmacher A,. Making sense of itraconazole pharmacokinetics. J Antimicrob Chemother 2005; 56 (Supplement S1): i 17 -i 22.
60. Lestner J, Hope WW,. Itraconazole: an update on pharmacology and clinical use for treatment of invasive and allergic fungal infections. Expert Opin Drug Metab Toxicol 2013; 9: 911-26.
61. Stockmann C, Constance JE, Roberts JK, Olson J, Doby EH, Ampofo K, Stiers J, Spigarelli MG, Sherwin CMT,. Pharmacokinetics and pharmacodynamics of antifungals in children and their clinical implications. Clin Pharmacokinet 2014; 53: 429-54.
62. Ito K, Ogihara K, Kanamitsu S, Itoh T,. Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes. Drug Metab Dispos 2003; 31: 945-54.
63. Galetin A, Burt H, Gibbons L, Houston JB,. Prediction of time-dependent CYP3A4 drug-drug interactions: impact of enzyme degradation, parallel elimination pathways, and intestinal inhibition. Drug Metab Dispos 2006; 34: 166-75.
64. Polasek TM, Miners JO,. Quantitative prediction of macrolide drug-drug interaction potential from in vitro studies using testosterone as the human cytochrome P4503A substrate. Eur J Clin Pharmacol 2006; 62: 203-8.
65. Rowland Yeo K, Walsky RL, Jamei M, Rostami-Hodjegan A, Tucker GT,. Prediction of time-dependent CYP3A4 drug-drug interactions by physiologically based pharmacokinetic modelling: impact of inactivation parameters and enzyme turnover. Eur J Pharm Sci 2011; 43: 160-73.
66. Fujioka Y, Kunze KL, Isoherranen N,. Risk assessment of mechanism-based inactivation in drug-drug interactions. Drug Metab Dispos 2012; 40: 1653-7.
67. Greenblatt DJ, von Moltke LL, Harmatz JS, Counihan M, Graf JA, Durol ALB, Mertzanis P, Duan SX, Wright CE, Shader RI,. Inhibition of triazolam clearance by macrolide antimicrobial agents: In vitro correlates and dynamic consequences. Clin Pharmacol Ther 1998; 64: 278-85.
68. Rodvold KA,. Clinical pharmacokinetics of clarithromycin. Clin Pharmacokinet 1999; 37: 385-98.
69. Chu SY, Sennello LT, Bunnell ST, Varga LL, Wilson DS, Sonders RC,. Pharmacokinetics of clarithromycin, a new macrolide, after single ascending oral doses. Antimicrob Agents Chemother 1992; 36: 2447-53.
70. Farkas D, Volak LP, Harmatz JS, von Moltke LL, Court MH, Greenblatt DJ,. Short-term clarithromycin administration impairs clearance and enhances pharmacodynamic effects of trazodone but not of zolpidem. Clin Pharmacol Ther 2009; 85: 644-50.
71. Zhou S, Chan E, Lim LY, Boelsterli UA, Li SC, Wang J, Zhang Q, Huang M, Xu A,. Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4. Curr Drug Metab 2004; 5: 415-42.
72. Fontana E, Dansette PM, Poli SM,. Cytochrome P450 enzymes mechanism based inhibitors: common sub-structures and reactivity. Curr Drug Metab 2005; 6: 413-54.
73. Venkatakrishnan K, Obach RS,. Drug-drug interactions via mechanism-based cytochrome P450 inactivation: points to consider for risk assessment from in vitro data and clinical pharmacologic evaluation. Curr Drug Metab 2007; 8: 449-62.
74. Zhou SF, Xue CC, Yu XQ, Li C, Wang G,. Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther Drug Monit 2007; 29: 687-710.
75. Quinney SK, Malireddy SR, Vuppalanchi R, Hamman MA, Chalasani N, Gorski JC, Hall SC,. Rate of onset of inhibition of gut-wall and hepatic CYP3A by clarithromycin. Eur J Clin Pharmacol 2013; 69: 439-48.
76. Okudaira T, Kotegawa T, Imai H, Tsutsumi K, Nakano S, Ohashi K,. Effect of the treatment period with erythromycin on cytochrome P450 3A activity in humans. J Clin Pharmacol 2007; 47: 871-6.
77. Eagling VA, Back DJ, Barry MG,. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br J Clin Pharmacol 1997; 44: 190-4.
78. von Moltke LL, Greenblatt DJ, Grassi JM, Granda BW, Duan SX, Fogelman SM, Daily JP, Harmatz JS, Shader RI,. Protease inhibitors as inhibitors of human cytochromes P450: High risk associated with ritonavir. J Clin Pharmacol 1998; 38: 106-11.
79. von Moltke LL, Durol ALB, Duan SX, Greenblatt DJ,. Potent mechanism-based inhibition of human CYP3A in vitro by amprenavir and ritonavir: comparison with ketoconazole. Eur J Clin Pharmacol 2000; 56: 259-61.
80. Rock BM, Hengel SM, Rock DA, Wienkers LC, Kunze KL,. Characterization of ritonavir-mediated inactivation of cytochrome P450 3A4. Mol Pharmacol 2014; 86: 665-74.
81. Mathias AA, West S, Hui J, Kearney BP,. Dose-response of ritonavir on hepatic CYP3A activity and elvitegravir oral exposure. Clin Pharmacol Ther 2009; 85: 64-70.
82. Culm-Merdek KE, von Moltke LL, Gan L, Horan KA, Reynolds R, Harmatz JS, Court MH, Greenblatt DJ,. Effect of extended exposure to grapefruit juice on cytochrome P450 3A activity in humans: Comparison with ritonavir. Clin Pharmacol Ther 2006; 79: 243-54.
83. Greenblatt DJ, von Moltke LL, Harmatz JS, Durol ALB, Daily JP, Graf JA, Mertzanis P, Hoffman JL, Shader RI,. Differential impairment of triazolam and zolpidem clearance by ritonavir. J Acquir Immune Defic Syndr 2000; 24: 129-36.
84. von Moltke LL, Greenblatt DJ, Duan SX, Daily JP, Harmatz JS, Shader RI,. Inhibition of desipramine hydroxylation (cytochrome P450-2D6) in vitro by quinidine and by viral protease inhibitors: Relation to drug interactions in vivo. J Pharm Sci 1998; 87: 1184-9.
85. Hesse LM, von Moltke LL, Shader RI, Greenblatt DJ,. Ritonavir, efavirenz, and nelfinavir inhibit CYP2B6 activity in vitro: Potential drug interactions with bupropion. Drug Metab Dispos 2001; 29: 100-2.
86. Sai Y, Dai R, Yang TJ, Krausz KW, Gonzalez FJ, Gelboin HV, Shou M,. Assessment of specificity of eight chemical inhibitors using cDNA-expressed cytochromes P450. Xenobiotica 2000; 30: 327-43.
87. Khojasteh SC, Prabhu S, Kenny JR, Halladay JS, Lu AY,. Chemical inhibitors of cytochrome P450 isoforms in human liver microsomes: a re-evaluation of P450 isoform selectivity. Eur J Drug Metab Pharmacokinet 2011; 36: 1-16.
88. Englund G, Lundquist P, Skogastierna C, Johansson J, Hoogstraate J, Afzelius L, Andersson TB, Projean D,. Cytochrome P450 inhibitory properties of common efflux transporter inhibitors. Drug Metab Dispos 2014; 42: 441-7.
89. Kubo M, Koue T, Inaba A, Takeda H, Maune H, Fukuda T, Azuma J,. Influence of itraconazole co-administration and CYP2D6 genotype on the pharmacokinetics of the new antipsychotic aripiprazole. Drug Metab Pharmacokinet 2005; 20: 55-64.
90. Saarikoski T, Saari TI, Hagelberg NM, Backman JT, Neuvonen PJ, Scheinin M, Olkkola KT, Laine K,. Effects of terbinafine and itraconazole on the pharmacokinetics of orally administered tramadol. Eur J Clin Pharmacol 2015; 71: 321-7.
91. Aarnoutse RE, Kleinnijenhuis J, Koopmans PP, Touw DJ, Wieling J, Hekster YA, Burger DM,. Effect of low-dose ritonavir (100 mg twice daily) on the activity of cytochrome P450 2D6 in healthy volunteers. Clin Pharmacol Ther 2005; 78: 664-74.
92. Hesse LM, Greenblatt DJ, von Moltke LL, Court MH,. Ritonavir has minimal impact on the pharmacokinetic disposition of a single dose of bupropion administered to human volunteers. J Clin Pharmacol 2006; 46: 567-76.
93. Perloff MD, von Moltke LL, Marchand JE, Greenblatt DJ,. Ritonavir induces P-glycoprotein expression, multidrug resistance-associated protein (MRP1) expression, and drug transporter-mediated activity in a human intestinal cell line. J Pharm Sci 2001; 90: 1829-37.
94. Dixit V, Hariparsad N, Li F, Desai P, Thummel KE, Unadkat JD,. Cytochrome P450 enzymes and transporters induced by anti-human immunodeficiency virus protease inhibitors in human hepatocytes: implications for predicting clinical drug interactions. Drug Metab Dispos 2007; 35: 1853-9.
95. Kirby BJ, Collier AC, Kharasch ED, Dixit V, Desai P, Whittington D, Thummel K, Unadkat J,. Complex drug interactions of HIV protease inhibitors 2: In vivo induction and in vitro to in vivo correlation of induction of cytochrome P450 1A2, 2B6, and 2C9 by ritonavir or nelfinavir. Drug Metab Dispos 2011; 39: 2329-37.
96. Penzak SR, Hon YY, Lawhorn WD, Shirley KL, Spratlin V, Jann MW,. Influence of ritonavir on olanzapine pharmacokinetics in healthy volunteers. J Clin Psychopharmacol 2002; 22: 366-70.
97. Khaliq Y, Gallicano K, Venance S, Kravcik S, Cameron DW,. Effect of ketoconazole on ritonavir and saquinavir concentrations in plasma and cerebrospinal fluid from patients infected with human immunodeficiency virus. Clinical Pharmacology & Therapeutics 2000; 68: 637-46.
98. Partanen J, Jalava KM, Neuvonen PJ,. Itraconazole increases serum digoxin concentration. Pharmacol Toxicol 1996; 79: 274-6.
99. Jalava KM, Partanen J, Neuvonen PJ,. Itraconazole decreases renal clearance of digoxin. Ther Drug Monit 1997; 19: 609-13.
100. Mathis AS, Friedman GS,. Coadministration of digoxin with itraconazole in renal transplant recipients. Am J Kidney Dis 2001; 37: E18.
101. Tateishi T, Miura M, Suzuki T, Uno T,. The different effects of itraconazole on the pharmacokinetics of fexofenadine enantiomers. Br J Clin Pharmacol 2008; 65: 693-700.
102. Tapaninen T, Backman JT, Kurkinen KJ, Neuvonen PJ, Niemi M,. Itraconazole, a P-glycoprotein and CYP3A4 inhibitor, markedly raises the plasma concentrations and enhances the renin-inhibiting effect of aliskiren. J Clin Pharmacol 2011; 51: 359-67.
103. Misaka S, Miyazaki N, Yatabe MS, Ono T, Shikama Y, Fukushima T, Kimura J,. Pharmacokinetic and pharmacodynamic interaction of nadolol with itraconazole, rifampicin and grapefruit juice in healthy volunteers. J Clin Pharmacol 2013; 53: 738-45.
104. Wakasugi H, Yano I, Ito T, Hashida T, Futami T, Nohara R, Sasayama S, Inui K,. Effect of clarithromycin on renal excretion of digoxin: Interaction with P-glycoprotein. Clin Pharmacol Ther 1998; 64: 123-8.
105. Rengelshausen J, Göggelmann C, Burhenne J, Riedel K-D, Ludwig J, Weiss J, Mikus G, Walter-Sack I, Haefeli WE,. Contribution of increased oral bioavailability and reduced non-glomerular renal clearance of digoxin to the digoxin-clarithromycin interaction. Br J Clin Pharmacol 2003; 56: 32-8.
106. Penzak SR, Shen JM, Alfaro RM, Remaley AT, Natarajan V, Falloon J,. Ritonavir decreases the nonrenal clearance of digoxin in healthy volunteers with known MDR1 genotypes. Ther Drug Monit 2004; 26: 322-30.
107. Ding R, Tayrouz Y, Riedel KD, Burhenne J, Weiss J, Mikus G, Haefeli WE,. Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers. Clin Pharmacol Ther 2004; 76: 73-84.
108. van Heeswijk RP, Bourbeau M, Campbell P, Seguin I, Chauhan BM, Foster BC, Cameron DW,. Time-dependent interaction between ritonavir induces/ritonavir and fexofenadine. J Clin Pharmacol 2006; 46: 758-67.
109. Kharasch ED, Bedynek PS, Walker A, Whittington D, Hoffer C, Park S,. Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: II. Ritonavir effects on CYP3A and P-glycoprotein activities. Clin Pharmacol Ther 2008; 84: 506-12.
110. Kirby BJ, Collier AC, Kharasch ED, Whittington D, Thummel KE, Unadkat JD,. Complex drug interactions of the HIV protease inhibitors 3: Effect of simultaneous or staggered dosing of digoxin and ritonavir, nelfinavir, rifampin, or bupropion. Drug Metab Dispos 2012; 40: 610-6.
111. Greenblatt DJ,. Antiretroviral boosting by cobicistat, a structural analog of ritonavir. Clinical Pharmacology in Drug Development 2014; 3: 335-7.
112. Xu L, Liu H, Murray BP, Callebaut C, Lee MS, Hong A, Strickley RG, Tsai LK, Stray KM, Wang Y, Rhodes GR, Desai MC,. Cobicistat (GS-9350): A potent and selective inhibitor of human CYP3A as a novel pharmacoenhancer. ACS Medicinal Chemistry Letters 2010; 1: 209-13.
113. Sevrioukova IF, Poulos TL,. Ritonavir analogues as a probe for deciphering the cytochrome P450 3A4 inhibitory mechanism. Curr Top Med Chem 2014; 14: 1348-55.
114. Lepist EI, Phan TK, Roy A, Tong L, MacLennan K, Murray B, Ray AS,. Cobicistat boosts the intestinal absorption of transport substrates, including HIV protease inhibitors and GS-7340, in vitro. Antimicrob Agents Chemother 2012; 56: 5409-13.